Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Inclusion Criteria: * 1\. Aged ≥18 years, with no gender restriction; * 2\. Patients with OAML confirmed by histopathology; * 3\. Ann Arbor stage (I\~II); * 4\. ECOG performance status score of 0-2; * 5\. No previous systemic treatment; * 6\. Major organ functions meet the following criteria: * (1). Blood routine: Absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥75×10⁹/L, hemoglobin ≥75g/L; In case of bone marrow involvement, absolute neutrophil count ≥1.0×10⁹/L, platelet count ≥50×10⁹/L, hemoglobin ≥50g/L; * (2). Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; Serum creatinine ≤1.5×ULN; Serum amylase ≤ULN; * (3). Coagulation function: International Normalized Ratio (INR) ≤1.5×ULN. * 7\. Expected survival time ≥3 months * 8\. Voluntarily sign a written informed consent form before trial screening. Exclusion Criteria: * 1\. Current or previous history of other malignant tumors, except those with evidence of no recurrence or metastasis for at least 5 years after radical treatment; * 2\. Lymphoma involving the central nervous system or transformed to high-grade lymphoma; * 3\. Non-hematological toxicities from previous anti-tumor treatment have not recovered to ≤ Grade 1 (except alopecia); * 4\. Uncontrolled or significant cardiovascular diseases, including: * (1). Congestive heart failure of New York Heart Association (NYHA) Class II or higher, unstable angina pectoris, myocardial infarction within 6 months before the first administration of the study d…